Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial.
acute coronary syndrome
cardiac
high-statin therapy
ldl
moderate-statin therapy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
22
12
2021
entrez:
2
2
2022
pubmed:
3
2
2022
medline:
3
2
2022
Statut:
epublish
Résumé
Statin use in secondary prevention after acute coronary syndrome (ACS) can play an important role in enhancing clinical outcomes, this has been proven in several randomized trials. This study was conducted to compare the efficacy of moderate-intensity and high-intensity statins in controlling low-density lipoprotein (LDL) after ACS. A randomized control trial was conducted at the Cardiology Department of Liaquat National Hospital, Karachi, Pakistan, from July 2020 to September 2021. During admission, patients were either started on a high-intensity statin dose (rosuvastatin 20 mg) or moderate-intensity statin (rosuvastatin 10 mg) by a computer-generated allocation sequence. Patients were followed-up in the outpatient department (OPD) after 3 months, and a lipid profile at follow-up was obtained. The percentage of LDL change was determined on 3 months of follow-up. A total of 590 patients were enrolled in the study. Out of all participants enrolled, 334 (80.48%) completed the 3-month follow-up. The mean age of participants was 58.08 (+12.06) years. High-intensity statin therapy is positively associated with positive LDL change (adjusted odds ratio [AOR]=4.45, P-value=0.001). Our data implies that high-intensity statin medication may be an initial therapeutic option to decrease LDL. However, future randomized clinical trials should corroborate these findings.
Identifiants
pubmed: 35106245
doi: 10.7759/cureus.20710
pmc: PMC8788888
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
e20710Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2021, Rupasinghe et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Pharmacol Ther. 2005 Oct;78(4):330-41
pubmed: 16198652
Atherosclerosis. 2014 Apr;233(2):707-712
pubmed: 24603217
J Am Coll Cardiol. 2009 Jul 21;54(4):293-302
pubmed: 19608026
Int J Cardiol. 2016 Feb 1;204:57-8
pubmed: 26655539
N Engl J Med. 2005 Apr 7;352(14):1425-35
pubmed: 15755765
Circ J. 2010 Aug;74(8):1731-41
pubmed: 20671372
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
Coron Artery Dis. 2016 Dec;27(8):636-649
pubmed: 27388482
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
Atherosclerosis. 2016 Oct;253:281-344
pubmed: 27594540
JAMA. 1998 May 27;279(20):1615-22
pubmed: 9613910
Eur J Clin Pharmacol. 2015 Mar;71(3):329-40
pubmed: 25630984
PLoS One. 2018 Dec 7;13(12):e0207889
pubmed: 30532220
N Engl J Med. 2017 Aug 17;377(7):633-643
pubmed: 28813214
Eur Heart J. 2015 Aug 14;36(31):2110-2118
pubmed: 25994746
Circulation. 2007 Mar 20;115(11):1363-70
pubmed: 17353444
PLoS One. 2017 Oct 26;12(10):e0186861
pubmed: 29073192
Ann Intern Med. 2010 Jan 19;152(2):69-77
pubmed: 20083825
Am Heart J. 2010 Dec;160(6):1121-9, 1129.e1
pubmed: 21146667
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Circ J. 2010 Aug;74(8):1718-30
pubmed: 20671371
Circ J. 2012;76(6):1369-79
pubmed: 22447012
N Engl J Med. 2004 Apr 8;350(15):1495-504
pubmed: 15007110